Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose Biosciences Announces Appointment of Dr. Erich Platzer to Board of Directors

Dec 15, 2014 8:00am EST

Aptose Biosciences Presents APTO-253 Preclinical Data at 56th American Society of Hematology Annual Meeting

Dec 09, 2014 8:00am EST

Aptose Biosciences to Present at Oppenheimer & Co. 25th Annual Healthcare Conference

Dec 05, 2014 8:00am EST

Aptose Biosciences to Present Preclinical Research Update for APTO-253 at the 56th American Society of Hematology Annual Meeting

Dec 03, 2014 8:00am EST

Aptose Biosciences to Present at The Stifel 2014 Healthcare Conference

Nov 17, 2014 8:00am EST

Aptose Biosciences reports results for the four months ended September 30, 2014

Nov 04, 2014 4:00pm EST

Aptose Biosciences To Host Conference Call and Webcast For Four Month Interim Period Ended September 30, 2014

Oct 30, 2014 7:01am EDT

Aptose Biosciences Announces Approval for Listing on the NASDAQ Capital Market Shares to Begin Trading Under the Symbol APTO

Oct 21, 2014 8:00am EDT

Aptose Biosciences to Present at the 2014 BIO Investor Forum

Oct 03, 2014 7:00am EDT

Aptose Biosciences Announces Reverse Stock Split

Oct 01, 2014 5:16pm EDT
RSS
  • Prev
    • 1...
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences